drugset / Trial / NCT00216346
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
RandomizedParallel-groupOpen-labelTreatment
Summary
Symptomatic Visceral Leishmaniasis(VL)is fatal; Due to the increasing resistance to standard therapy with antimonials, there is a need for new safe, efficacious, low-cost therapies for the treatment of VL. Paromomycin is an off-patent aminoglycoside antibiotic with anti-leishmaniasis activity. This study will test the safety and efficacy of paromomycin in the treatment of patients with VL in India.
Timeline
- Start
- 2003-06
- Primary completion
- —
- Completion
- 2004-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amphotericin B | Unknown | 1 mg/kg | Intravenous |
| Subject | Paromomycin | Small molecule | 11 mg/kg | Intramuscular |